Finanzen von CVS Health Corp (CVS)CVSCVS Health Corp

CVS Health Corporation (CVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pharmacy, accounting for 36.1% of total sales, equivalent to $38.25B. Other significant revenue streams include Premiums and Front Store. Understanding this composition is critical for investors evaluating how CVS navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, CVS Health Corporation maintains a gross margin of 14.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 4.44%, while the net margin is 2.82%. These profitability ratios, combined with a Return on Equity (ROE) of 6.23%, provide a clear picture of how effectively CVS converts its operational activities into shareholder value.

In the context of the broader market, CVS competes directly with industry leaders such as GRDN. With a market capitalization of $115.61B, it holds a leading position in the sector. When comparing efficiency, CVS's gross margin of 14.84% stands against GRDN's 22.75%. Such benchmarking helps identify whether CVS Health Corporation is trading at a premium or discount relative to its financial performance.

CVS has shown a consistent revenue increase, with Q2 2026 revenue at $106.1 billion, and a gross margin of 14.84%. However, net income has fluctuated, with a significant drop in Q3 2025 to -$3.975 billion, highlighting volatility in earnings.